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Abstract 
 
Pediatric tumors harbor very low numbers of somatic mutations and therefore offer few 
targets to improve therapeutic management with targeted drugs. In particular, 
outcomes remain dismal for patients with metastatic alveolar rhabdomyosarcoma 
(aRMS), where the chimeric transcription factor PAX3/7-FOXO1 has been implicated but 
problematic to target. In this report, we addressed this challenge by developing a two-
armed screen for druggable upstream regulatory kinases in the PAX3/7-FOXO1 
pathway. Screening libraries of kinome siRNA and small molecules, we defined PLK1 as 
an upstream-acting regulator. Mechanistically, PLK1 interacted with and 
phosphorylated PAX3-FOXO1 at the novel site S503 leading to protein stabilization. 
Notably, PLK1 inhibition led to elevated ubiquitination and rapid proteasomal 
degradation of the PAX3-FOXO1 chimeric oncoprotein. On this basis, we embarked on a 
preclinical validation of PLK1 as target in a xenograft mouse model of aRMS, where the 
PLK1 inhibitor BI 2536 reduced PAX3-FOXO1-mediated gene expression and elicited 
tumor regression. Clinically, analysis of human aRMS tumor biopsies documented high 
PLK1 expression to offer prognostic significance for both event-free and overall survival. 
Taken together, these preclinical studies validate the PLK1 - PAX3-FOXO1 axis as a 
rational target to treat alveolar rhabdomyosarcoma.  
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Introduction  
 
Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma and can be 
divided into two main subgroups with different outcomes reflecting distinct genetic 
backgrounds. Alveolar rhabdomyosarcoma (aRMS) is more aggressive than embryonal 
rhabdomyosarcoma (eRMS) and often displays resistance to conventional chemo- and 
radiotherapy resulting in a 5-year survival rate of only 30% (1). Until now, there are no 
alternative therapeutic strategies to these conventional treatments. Searching for 
appropriate molecular targets, large proteomic screening and sequencing approaches 
have been undertaken showing that pediatric tumors harbor far fewer somatic 
mutations than adult tumors (2). In contrast to eRMS, analyzing genetic landscapes of 
alveolar rhabdomyosarcoma even further minimized the number of potential targets 
and excluded enrichment of any mutated oncogenic canonical pathway in the majority 
of patients (3, 4). These findings indicate that aRMS is driven by very few individual 
oncogenes and consequently reinforce the focus on the role of the tumor specific 
chimeric transcription factor PAX3/7-FOXO1.  
The fusion protein is expressed in about 80% of aRMS tumors suggesting a dominant 
role as oncogenic driver (4, 5). Its transforming capacity (6, 7) is underlined by the 
ability to affect multiple oncogenic downstream pathways (8-13). Furthermore, aRMS is 
addicted to expression of the fusion protein as its continuous activity is essential for 
maintaining tumor cell survival (14, 15). Finally, its presence has also important 
prognostic significance (16, 17). PAX3-FOXO1 is, in conclusion, a highly relevant 
potential target and offers the opportunity for development of novel directed therapies. 
However, directly antagonizing transcription factors remains a pharmaceutical 
challenge and alternative indirect strategies interfering with the regulatory network of 
the fusion protein need to be developed. 
PAX3-FOXO1 is characterized by high expression, exclusive nuclear subcellular 
localization, enhanced protein stability, and increased transcriptional activity compared 
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to wild type PAX3 or FOXO1 (18-22). Currently, we aim to mechanistically understand 
these different levels of regulation required for the oncogenic function. We, as well as 
others, were able to demonstrate that the transcriptional activity of PAX3-FOXO1 
depends on its phosphorylation state providing novel therapeutic opportunities (23-
25). 
Polo-like kinase 1 (PLK1) is known as key regulator of mitosis with critical roles in 
mitotic entry, centrosome maturation, cohesin release, bipolar spindle formation, 
mitotic exit, and cytokinesis. Overexpression of PLK1 is linked to poor prognosis in a 
variety of different cancers (26, 27). In contrast to healthy cells, it localizes to the 
nucleus already before G2-M in cancer cells and can be detected during the entire 
interphase (28). Therefore, cancer-cell specific functions in G1-S transition and DNA 
replication are suggested beyond its role in regulation of mitosis. Interestingly, PLK1 is 
associated with PI3K and MAPK pathways, both of which are thought to play important 
roles in aRMS (29, 30). Hence, PLK1 overexpression might not just be a consequence of 
enhanced proliferation, but it is likely that PLK1 actively contributes to early 
carcinogenesis. However, a specific role for PLK1 in aRMS has not yet been described. 
Here, we utilized a two-armed screening strategy to identify PLK1 as upstream 
regulator of PAX3-FOXO1, whereby PLK1 phosphorylated and subsequently stabilized 
the fusion protein. Since we observed objective regression of xenograft tumors upon 
PLK1 inhibition and found that PLK1 expression in patient biopsies has significant 
prognostic value, we propose the PLK1 – PAX3-FOXO1 axis to be a very promising novel 
target for aRMS therapy. 
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Material and Methods 
Cell lines 
The aRMS cell lines Rh4, Rh41 (Peter Houghton, St. Jude Children's Hospital, Memphis, 
TN, USA), RMS13 (Roland Kappler, Ludwig–Maximilian University Munich, Germany), 
Rh3, Rh5, Rh10 (Susan Ragsdale, St. Jude Children's Hospital, Memphis, TN, USA), 
CW9019 (Soledad Gallego, Hospital Universitari Vall d'Hebron, Barcelona, Spain) and 
Rh30 as well as HEK293T cells (American Type Culture Collection ATCC, LGC 
Promochem, Molsheim Cedex, France) were cultured in Dulbecco's modified Eagle's 
medium (Sigma-Aldrich, Buchs, Switzerland), supplemented with 100 U/ml 
penicillin/streptomycin, 2 mM L-glutamine and 10% FBS (Life Technologies, Zug, 
Switzerland) in 5% CO2 at 37°C. RD and Rh36  eRMS cells were kindly provided by Peter 
Houghton (St. Jude Children's Hospital, Memphis, TN, USA).  Ruch2 and Ruch3 cell lines 
were established in our laboratory (31).  
aRMS and eRMS cell lines were tested and authenticated by cell line typing analysis (STR 
profiling) in 2011/2014 and positively matched (32). 
 
Plasmids and transfection methods 
Plasmids and transfection methods are described in Supplementary Material and 
Methods. 
 
siRNA kinome library screens and data analysis 
A kinome siRNA library targeting 719 kinases was used (Ambion Silencer® V3 Kinase 
siRNA Library, Life Technologies, Zug, Switzerland) together with a sub-library targeting 
47 kinases (Ambion Silencer® Select Costum siRNA Library, Life Technologies) with 3 
unique siRNA sequences per gene. Ambion non-targeting siRNA served as negative 
control, whereas PAX3-FOXO1 break-point specific siRNA (33), luciferase specific siRNA 
(pGL4, Custom Select) and KIF11 siRNA (AM4639; all Ambion, Life Technologies) were 
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used as positive controls. Reverse transfection was carried out with 1x104 cells per 96-
well at a final concentration of 50 nM using N-TER nanoparticle transfection reagent 
(Sigma-Aldrich). Luciferase activity was determined by the Luciferase Assay System 
E1501 (Promega, Dübendorf, Switzerland) 48h post transfection and values normalized 
to viable cell numbers determined by WST-1 assay (Roche Diagnostics, Rotkreuz, 
Switzerland). Measurements were normalized using the per-plate median normalization 
method (excluding controls). Triplicate median-normalized luciferase values were 
averaged for each kinase before calculating the ratio to the averaged WST-1 absorbance 
(normalized luciferase activity). Cell viability of Rh4 and RMS13 cells was measured 72h 
post transfection using WST-1. Both screens were done in triplicates and non-targeting, 
PAX3-FOXO1, pGL4 and KIF11 siRNAs were included in duplicates on each plate. 
 
Small-molecule compounds screen and dose response studies 
A small-molecule compound library (Supplementary Tab. S2) covering 161 different 
inhibitors was used to treat 5x103 Rh4-AP2-LF cells per 96-well 24h after plating at a 
final concentration of 500 nM for 24h. Luciferase activity/cell viability ratio was 
determined as described above. For dose response curves, this ratio was plotted against 
the logarithm of drug concentrations and IC50 values were calculated by nonlinear 
regression curve fitting using GraphPad Prism software (GraphPad Software Inc., San 
Diego, CA, USA). 
 
PLK1 silencing and small-molecule inhibition 
Knockdowns of PLK1 and PLK4 were achieved by reverse transfection of 1.9-3.8x105 
cells in 6-well plates using scrambled (4390846) or PLK1 and PLK4 directed siRNAs (25 
nM 1341, 8 nM S449, 25 nM S21083; all Ambion, Life Technologies) with INTERFERinTM 
according to the manufacturer’s protocol (Polyplus-Transfections, Illkirch, France). Cells 
were lysed 48h post transfection.  
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2x105 cells per 6-well were treated 24h after seeding with 15 nM BI 2536 (Axon 
Medchem, Groningen, Netherlands) or 20 nM BI 6727 (Selleck Chemicals, Houston TX, 
USA). Cells were lysed for RNA or protein extraction after 48h. For proteasomal 
degradation studies, 10 nM - 50 nM Bortezomib (Cilag, Schaffhausen, Switzerland) was 
simultaneously added and cells were lysed after 20h. 
 
qRT- PCR 
Total RNA was extracted using the Qiagen RNeasy Kit (Qiagen, Basel, Switzerland) and 
reverse-transcribed using oligo (dT) primers and Omniscript reverse transcriptase 
(Qiagen). qRT-PCR was performed for PLK1 (Hs00153444_m1), PLK4 
(Hs00179514_m1), PAX3-FOXO1 (Hs03024825_ft), AP2β (Hs00231468_m1), FGFR4 
(Hs01106908_m1), CDH3 (Hs00999918_m1), PIPOX (Hs04188864_m1) and MYL1 
(Hs00984899_m1) using TaqMan gene expression master mix (all Life Technologies). 
Cycle threshold (CT) values were normalized to GAPDH (Hs02758991_g1). Relative 
expression levels were calculated using the ΔΔCT method based on experiments 
performed in triplicates. Geometric mean values and the 95% confidence interval were 
calculated based on four to six biological replicates. 
 
Immunoblotting 
Total cell extracts were separated using 4-12% Bis-Tris SDS-PAGE gels (Life 
Technologies) and transferred to nitrocellulose membranes (PROTAN, Schleicher & 
Schuell, Kassel, Germany). After blocking with 5% milk powder in TBS/0.1% Tween, 
membranes were incubated with primary antibodies overnight at 4°C. After washing in 
TBS/0.1% Tween, membranes were incubated with IgG HRP-linked antibody for one 
hour at room temperature. Proteins were detected using ECL detection reagent (Fisher 
Scientific, Wohlen, Switzerland) after washing in TBS/0.1% Tween.  
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Antibodies 
Antibodies are described in Supplementary Material and Methods. 
 
Co-immunoprecipitation 
Cells from one confluent 10 cm dish were lysed in 1 ml lysis buffer and incubated for 10 
min at 4°C with Dynabeads® Protein G (Novex by Life Technologies) coupled to 
indicated antibodies. Beads were washed three times with lysis buffer, proteins eluted 
in 1x NuPAGE LDS sample buffer (Life Technologies) at 70°C and analyzed by Western 
blotting. 
 
Stability assay 
2x105 RD cells were seeded per 6-well the day before transfection with 1 μg pMSCV-
PAX3-FOXO1-IRES-GFP or pMSCV-PAX3-FOXO1-S503A-IRES-GFP. Cells were treated 
with 35 μM cycloheximide (Sigma-Aldrich) or DMSO for 6h before lysis and protein 
extraction. Protein levels were analyzed by Western blotting. 
 
Purification of FLAG-PAX3-FOXO1  
Rh4, RMS13 or HEK293T cells were transfected with pCMV-NFLAG-PAX3-FOXO1 in 15 
cm plates, lysed 40h post transfection and FLAG-PAX3-FOXO1 was immunoprecipitated 
using 75 μl Dynabeads® per plate coupled to 8 μg monoclonal ANTI-FLAG® M2 antibody. 
After washing, bead-bound FLAG-PAX3-FOXO1 was either used for in vitro kinase assays 
or the protein was eluted by 1x NuPage LDS buffer and directly subjected to mass 
spectrometry. 
 
In vitro kinase assay and mass spectrometry 
Bead-bound protein was dephosphorylated using 300 units CIAP enzyme (alkaline 
phosphatase, calf intestinal HC, Promega, Dübendorf, Switzerland) for 90 min at 37°C 
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(50 mM Tris HCl pH 7.5, 1 mM MgCl2, 0.1 mM ZnCl2). FLAG-PAX3-FOXO1 was 
phosphorylated after washing using 500 ng or 2.5 μg of recombinant PLK1 (Life 
Technologies) for 30 min at 30°C (250 mM HEPES pH 7.5, 50 mM MgCl2, 12.5 mM DTT, 
0.05% Triton X-100, 200 μM ATP). 4x NuPage LDS buffer was added for elution and 
proteins were separated by gel electrophoresis. After staining with colloidal coomassie 
(Instant blue, Expedeon, Harston, UK), the band corresponding to FLAG-PAX3-FOXO1 
was excised and prepared for mass spectrometry as described in Supplementary 
Material and Methods. 
 
Ubiquitination studies 
Rh4 cells were transfected with pCMV-FLAG-PAX3-FOXO1 plasmid and pCDNA3-HA-
Ubiquitin at a ratio of 1:2 for 48h. Cells were treated with 200 nM PLK1 inhibitors for 
21h prior to addition of 10 μM MG-132 (Calbiochem, Millipore, Zug, Switzerland) for 5h. 
After lysis (2% SDS, 150 mM NaCl, 10 mM Tris/HCl, 2 mM Na3VO4, 50 mM NaF), samples 
were boiled for 10 min, sonicated, diluted with 9 volumes of dilution buffer (150 mM 
NaCl, 10 mM Tris/HCl, 2 mM EDTA, 1% TritonX) and incubated for 30 min at 4°C. IP was 
performed using Dynabeads® coupled to ANTI-FLAG® M2 antibody for 1h at 4°C. Beads 
were washed three times with lysis buffer, proteins eluted with 3x FLAG peptide 
(Sigma-Aldrich) and analyzed by Western blotting. 
 
Xenograft studies 
5x106 Rh4, Rh4luc or RMS13luc cells were engrafted subcutaneously in 6 weeks old 
NOD/Scid il2rg-/- mice (male and female, 20-25 g, Charles River, Sulzfeld, Germany). 
Mice bearing established tumors with volumes of 65 – 470 mm3 were treated 
intravenously with either sterile 0.9% NaCl or BI 2536 at 40 mg/kg on two consecutive 
days weekly for three cycles. BI 2536 was formulated in hydrochloric acid (0.1 N) 
diluted with 0.9% NaCl (34). Total tumor volumes were determined either by measuring 
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two diameters (d1, d2) in right angles using a digital caliper (V= (4/3) π r³; r= 
(d1+d2)/4) or by in vivo imaging. D-luciferin (Caliper Life Sciences, Oftringen, 
Switzerland) was injected intraperitoneally (10 µl/g body weight), and tumors were 
monitored by the IVIS Lumina XR imaging system (Caliper Life Sciences). Control mice 
were euthanized when reaching a tumor volume of 1000 mm3.  
 
Immunohistochemistry 
Three-micron thick sections of formalin-fixed, paraffin-embedded tissue were mounted 
on glass slides (SuperFrost Plus; Menzel, Braunschweig, Germany), deparaffinized, 
rehydrated and stained with hematoxylin and eosin (H&E). Immunohistochemical 
stainings were performed using the Ventana Benchmark system (Ventana Medical 
Systems, Tucson, AZ) and Ventana UltraView DAB reagents. 
 
Tissue arrays 
Tissue arrays have been previously described (35, 36). Immunohistochemistry was 
performed on Leica BondMax instruments using Refine HRP-Kits (Leica DS9800, Leica 
Microsystems Newcastle, Ltd.). Paraffin-slides were dewaxed, followed by pretreatment 
(Epitop Retrieval Buffer 2, 45 min, 100°C) and incubated with anti-PLK1 antibody 
(1:600). Tumors showing at least 1-5% of cells with a very high staining intensity were 
assigned to the high expression group. In contrast, tumors with low expression showed 
homogenous overall staining of reduced intensity. TMAs were analyzed double-blinded. 
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Results 
Kinome-wide siRNA screen identifies PAX3-FOXO1 regulators  
To identify kinases regulating the activity of the oncogenic transcription factor PAX3-
FOXO1, we established a stable reporter cell line to monitor fusion protein activity (Fig. 
1A). Rh4 aRMS cells with a transcriptome very similar to tumor biopsies (13) were 
stably transfected with a PAX3-FOXO1-responsive luciferase reporter employing a well-
characterized endogenous AP2β promoter fragment (10) to generate Rh4-AP2β-LF cells. 
Depletion of PAX3-FOXO1 by siRNA (33) or silencing of luciferase itself resulted in a 
more than 70% decrease in luciferase activity (Supplementary Fig. S1A). Therefore, this 
reporter assay constitutes a valid tool for functional screening of PAX3-FOXO1 upstream 
regulators.  
First, we performed a kinome-wide siRNA screen (Figure 1A). Rh4-AP2β-LF cells were 
transfected with three unique siRNA sequences targeting each of the 719 kinases (Fig. 
1B and Supplementary Fig. S1B). PAX3-FOXO1, KIF11 (mitotic motor protein) and 
luciferase control siRNAs were included on each plate and the ratio of luciferase activity 
to cell viability from averaged triplicate values was determined for each siRNA. Only 
siRNAs that reduced this ratio by at least 1.5 SDs from the mean of the luciferase control 
were considered as potential candidates. Applying this criterion for at least two 
independent siRNAs, we identified 47 candidates that potentially contribute to the 
activity of PAX3-FOXO1 (Supplementary Tab. S1). Importantly, these kinases are all 
expressed in Rh4 cells and primary aRMS tumors, at least at the mRNA level (9, 13). 
To narrow down the list of candidates, we applied a secondary viability screen using an 
siRNA library containing three additional targeting sequences per kinase (sequence 
panels A, B and C). We determined mean relative cell viability after individual silencing 
for 72 hours in Rh4 and RMS13 cells.  Next to two positive controls (PAX3-FOXO1 and 
KIF11) included on each screening plate, we found that knockdown of PLK1 clearly had 
the strongest impact on cell viability in both cell lines (up to 61% reduction), whereas 
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the per-plate means reached only 7% to 22% (Fig. 1C). These results suggest that PLK1 
expression might be important for aRMS cell survival. 
 
Small-molecule inhibitor screen reveals PLK1 as potential PAX3-FOXO1 regulator 
In parallel to the siRNA screen, we conducted a small-molecule, mainly kinase-directed 
drug screen, to further examine the regulation of PAX3-FOXO1 activity (Fig. 1A).  This 
approach is able to directly identify available pharmaceutical inhibitory compounds. We 
treated Rh4-AP2β-LF cells with 161 inhibitors (Supplementary Tab. S2) at a final 
concentration of 500 nM and measured cell viability as well as luciferase activity after 
24 hours.  Ranking compound activity according to ratio of luciferase activity over cell 
viability, 10 out of 161 inhibitors reduced normalized luciferase activity by at least 44% 
compared to untreated Rh4-AP2β-LF cells (Fig. 1D).  With a normalized luciferase 
reduction by 76% (relative ratio 0.24), the top candidate was the PLK1 inhibitor BI 2536 
(34).  
To further validate BI 2536, Rh4-AP2β-LF were treated with increasing concentrations 
for 24 hours. This resulted in a dose dependent reduction of normalized luciferase 
activity with an IC50 of 17.40 nM (Fig 1E; IC50/48h =15.75 nM; IC50/72h =10.20 nM, 
Supplementary Fig. S1C). Interestingly, the median IC50 value of aRMS cell lines was 
15.03 nM versus a median IC50 of 31.86 nM in eRMS cell lines (Supplementary Fig. S2A). 
PLK1 inhibition by BI 2536 induced apoptosis in Rh4 cells as shown by PARP cleavage 
(Supplementary Fig. S2B) as well as by relative increase in caspase 3/7 activity 
(Supplementary Fig. S2C). To demonstrate the potential relevance of PLK1 in aRMS, we 
analyzed the expression of PLK1 protein across a panel of eight different aRMS cell lines 
by immunoblotting. All of the cell lines expressed the kinase with Rh4, Rh41 and RMS13 
cells displaying the highest protein levels (Fig. 1F).  
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In conclusion, we identified PLK1 as the most promising candidate kinase by both siRNA 
and small-molecule compound screen, which therefore represents a potential target for 
treatment of aRMS.   
 
PLK1 inhibition reduces PAX3-FOXO1 activity  
To confirm PLK1 as regulator of the fusion protein, we analyzed a panel of PAX3-FOXO1 
target genes. We measured relative mRNA expression of the activated target genes 
AP2β, FGFR4, CDH3 and PIPOX (8, 9, 12, 13, 36-38) and the repressed differentiation 
marker MYL1 (39) by qRT-PCR after 48 hours of either PLK1 silencing (si1341 and 
siS449) or small-molecule inhibition (BI 2536 and BI 6727). In RMS13 cells, knockdown 
of PLK1 achieved 80% (si1341) and 82% (siS449) of silencing without affecting PAX3-
FOXO1 mRNA expression. However, expression of all target genes was significantly 
modulated (Fig. 2A). In Rh4 cells, knockdown efficiencies by si1341 reached 86% with 
similar modulation of target gene expression, whereas silencing by siS449 reached 81% 
without significant effects on target genes (Fig. 2B). Nevertheless, treatment with both 
inhibitors, BI 2536 and BI 6727, significantly affected target gene expression in both cell 
lines.  
In summary, PLK1 inhibition, either by genetic or pharmacological means, significantly 
altered transcription of PAX3-FOXO1 downstream targets suggesting a specific link 
between the kinase and the fusion protein. 
 
PLK1 binds to and phosphorylates PAX3-FOXO1  
We assessed direct interaction of PLK1 and PAX3-FOXO1 by co-immunoprecipitation of 
the endogenous proteins in Rh4 cells. PAX3-FOXO1 was pulled down using either anti-
PAX3 or anti-FOXO1 antibody. In both cases, PLK1 was co-immunoprecipitated with the 
fusion protein but not with the negative control as shown by Western blot analysis (Fig. 
3A). In a reciprocal approach, the kinase was pulled down by anti-PLK1 antibody and 
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PAX3-FOXO1 was found to co-immunoprecipitate as well (Fig. 3B). These findings 
indicate that PLK1 and PAX3-FOXO1 can directly interact in aRMS cells. 
Furthermore, we interrogated this interaction under drug treatment conditions. Rh4 
cells were transfected with FLAG-tagged PAX3-FOXO1 or FLAG-tagged GFP, which were 
then immunoprecipitated after DMSO or BI 2536 treatment for 16 hours using an anti-
FLAG antibody. Again, we found PLK1 to interact with the fusion protein, but not with 
GFP (Fig. 3C). Surprisingly, interaction even increased after treatment with BI 2536, 
which arrested cells in G2-M (Supplementary Fig. S2D and (34, 40)). This indicates that 
PLK1 might control PAX3-FOXO1 mainly at the transition to mitosis. 
PLK1 substrates contain the consensus motifs [D/E/N]Xp[S/T] or p[S/T]F (41) and 
several of these can also be found in PAX3-FOXO1 suggesting that it might be a direct 
target of PLK1. In silico analysis using GPS-Polo 1.0 (42) predicted S503 and S457 as 
potential phosphorylation sites with a high cut-off threshold (Fig. 3D). To directly 
analyze whether one of these consensus sites is phosphorylated in the fusion protein, 
FLAG-tagged PAX3-FOXO1 was purified from aRMS cells. Using mass spectrometry, we 
identified the peptide TSSNASTISGR containing S503 as one out of eleven phospho-
peptides (Supplementary Tab. S3). Furthermore, applying a phospho-specific antibody 
to exactly localize the phosphorylated residue, we detected phosphorylation at 
S503+S506 (corresponding to phospho-S322+S325 in FOXO1 against which the 
antibody is directed) directly demonstrating that the predicted site is phosphorylated in 
aRMS cells (Fig. 3E).  
To assess whether PLK1 can phosphorylate S503, we purified FLAG-PAX3-FOXO1 from 
HEK293T cells, dephosphorylated the protein by calf intestine alkaline phosphatase 
(CIAP) and subsequently performed in vitro kinase assays using recombinant PLK1. 
Mass spectrometry confirmed that PLK1 phosphorylated the peptide TSSNASTISGR. In 
total, this peptide contains six serine or threonine sites, but the data indicated that only 
S503 or T504 could be considered as potential phosphorylation sites (Supplementary 
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Fig. S3). To distinguish these two possibilities, we used the phospho-specific antibody 
recognizing phospho-S503+S506. Western blot analysis indeed revealed specific 
phosphorylation at these positions indicating that S503 is the site being phosphorylated 
by PLK1 (Fig. 3F).  
These data suggest that PLK1 and PAX3-FOXO1 are direct interaction partners and that 
PLK1 can phosphorylate the fusion protein at S503.  
 
PLK1 stabilizes PAX3-FOXO1 protein  
To further explore the biological functions of this phosphorylation site, we transfected 
RD eRMS cells lacking endogenous PAX3-FOXO1 with plasmids expressing either PAX3-
FOXO1 wild type or mutated PAX3-FOXO1-S503A. Cells were then treated with 
cycloheximide for 6 hours to assess protein turnover by immunoblotting and 
densitometric quantification. Interestingly, the mutant protein was significantly less 
stable than the wild type protein (protein amount reduced by 47%) (Fig. 4A and 4B).  
Next, the stability of endogenous PAX3-FOXO1 upon PLK1 depletion was examined in 
two aRMS cell lines. Treatment with 8 nM siRNA 1341 for 48 hours reduced PLK1 
protein by 43% in RMS13 cells and 53% in Rh4 cells respectively and induced a slight 
degradation of PAX3-FOXO1 (23% and 11%, calculated from representative blots shown 
in Fig. 4C). Upon silencing with the more efficient siRNA S449  (reduction of PLK1 by 
94% (RMS13) and 83% (Rh4)), we observed degradation of the fusion protein by 48% 
and 41% compared to scrambled control treatment (Fig. 4D). These results suggest that 
stability of PAX3-FOXO1 is modulated by phosphorylation at S503. Indeed, inhibition of 
PLK1 activity by BI 2536 (15 nM) and BI 6727 (20 nM) led to similar reduction of PAX3-
FOXO1 protein levels (53% and 64% in RMS13, 44% and 49% in Rh4 cells) (Fig. 4E). In 
addition, increased ubiquitination of PAX3-FOXO1 upon PLK1 inhibition confirmed its 
proteasomal degradation (Fig. 4F), which moreover, could be rescued by adding low 
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concentrations of the proteasomal inhibitor Bortezomib (43) in a dose dependent 
manner (Fig. 4G).  
In conclusion, these experiments imply that PLK1-mediated phosphorylation at S503 
protects PAX3-FOXO1 from ubiquitination and consequent proteasomal degradation 
and thus maintains the transcriptional activity of the fusion protein. 
 
PLK1 inhibition causes tumor regression in xenografts 
Based on our in vitro results, we further validated PLK1 as an in vivo target using 
xenograft mouse models. Immunocompromised NOD/Scid il2rg-/- (NSG) mice were 
engrafted subcutaneously with Rh4, Rh4luc and RMS13luc cells expressing luciferase for 
in vivo imaging. Mice with established tumors of varying sizes (65 mm3 – 470 mm3) 
were treated intravenously with vehicle or BI 2536 at a dose of 40 mg/kg for three 
weeks on two consecutive days per week (34). Every treatment group of three to five 
mice included two mice with large tumors of at least 300 mm3. Absolute tumor volumes 
measured by caliper in mice bearing Rh4 tumors revealed a complete tumor regression 
upon BI 2536 treatment in all mice, even when the starting volume was as high as 370 
mm3 (Fig. 5A). Similarly, luciferase activity was reduced in both cell lines by close to 
100% (Fig. 5A and 5B). Tumors of additional mice were treated for two cycles only, 
isolated after a two-week recovery phase, paraffin-embedded, and 
immunohistochemically stained. Vehicle treated tumors showed highly cellular 
histology with strong expression of Myogenin and AP2β consistent with aRMS. In 
contrast, treated xenografts displayed a high degree of necrotic areas and fibrosis. 
Importantly, expression of PAX3-FOXO1 target genes AP2β and P-Cadherin (CDH3) was 
significantly lower compared to untreated xenografts. 
These data impressively illustrate that PLK1 activity plays a major role in aRMS tumor 
cell survival corroborating our in vitro results. Therefore, PLK1 inhibitors such as BI 
2536 might represent very potent novel treatment options for aRMS.  
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PLK1 is overexpressed in human tumor biopsies and correlates with PAX3-FOXO1 
activity and survival 
To ensure that our findings are not restricted to aRMS cell lines, PLK1 expression was 
analyzed in patient tumor biopsies. We utilized PLK mRNA expression data of PAX3-
FOXO1 positive aRMS tumors from two independent data sets (9, 13) and compared 
them to PLK expression in normal muscle tissue (44). We found that mRNA levels of 
PLK1 and PLK4, but not PLK2 and PLK3, were significantly higher in tumor samples 
than in normal muscle biopsies (Fig. 6A and Supplementary Fig. S4).  
To validate PLK1 as a clinically relevant therapeutic target, we immunohistochemically 
stained a tissue microarray including tumor biopsies of 49 aRMS patients. Tumors were 
divided into high and low expressing subgroups as described in Material and Methods  
(Fig. 6B). To correlate PAX3-FOXO1 activity with PLK1 expression in vivo, we assessed in 
parallel expression of the PAX3-FOXO1 target gene AP2β. In a majority of tumors (34 
out of 45), AP2β staining from the same tumor significantly correlated with expression 
of PLK1 (Pearson correlation p-value: 0.0004, Fig. 6C). This was not the case for co-
staining with the proliferation marker MIB1 (Supplementary Fig. S5). These results 
support our previous findings and a mechanism whereby activity of PAX3-FOXO1 is 
modulated by PLK1. 
Importantly, outcome as measured for event free (EFS) and overall survival (OS) by 
Kaplan-Meier analysis was significantly worse for patients with high PLK1 expression 
(Fig. 6D). Five-year survival rates for patients in the PLK1 high expression cohort were 
only 15.4% (EFS) and 20.2% (OS). Therefore, the hazard ratio for events was 2.3 times 
higher (Wald test: p = 0.019) and for death even 3.16 times higher (Wald test: p = 0.004) 
for patients with high PLK1 expression. Moreover, multivariate analyses including the 
factors age, sex and tumor localization identified PLK1 status as the only significant risk 
associated variable (Tab. 1). The very dismal survival rates for the high expression 
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cohort emphasize the importance of PLK1 expression and suggest that PLK1 is a 
prognostic risk factor for fusion-positive RMS. 
In summary, our results imply that PLK1 is a highly attractive target for the treatment of 
aggressive aRMS, which warrants further investigations in clinical studies. 
 
Discussion 
This study describes a novel PLK1 - PAX3-FOXO1 oncogenic axis in aRMS. We show 
modulation of PAX3-FOXO1 activity by PLK1 based on direct protein-protein interaction 
and phosphorylation at S503 leading to stabilization of the fusion protein. In addition, in 
vivo treatment with PLK1 inhibitor demonstrated tumor regression and 
immunohistochemical analysis of PLK1 protein expression in human biopsies revealed 
its novel prognostic impact.  
To improve previous screenings for targets in aRMS, which concentrated mainly on cell 
viability (45), we focused on transcriptional activity of PAX3-FOXO1 by employing aRMS 
(Rh4) cells stably expressing an AP2β-promoter reporter construct. Using the ratio of 
reporter activity versus cell viability, we were able to exclude generally cytotoxic drugs. 
Strikingly, a kinome-wide siRNA as well as a small-molecule library screen identified 
PLK1 as top hit. KEGG pathway analysis (string-db.org) showed that several additional 
candidates are associated with MAPK or phosphatidylinositol signaling, both of which 
have been previously reported in RMS (27). 
To confirm PLK1 as an upstream modulator of PAX3-FOXO1 activity, we assessed 
expression of known endogenous PAX3-FOXO1 target genes (AP2β, FGFR4, CDH3, 
PIPOX and MYL1) upon inhibition by two drugs as well as by two different siRNAs in 
two aRMS cell lines. We observed significant target gene modulation with the exception 
of one siRNA in Rh4 cells. It is likely that the lack of activity might be due to 
compensatory effects by other members of the PLK family since BI 2536 and BI 6727 are 
known to affect the activities of PLK2, PLK3 and potentially PLK4 (34, 46). Indeed, next 
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to PLK1 also PLK4 is overexpressed in aRMS biopsies compared to normal muscle and, 
although not identified in the primary screen, its depletion reduced target gene 
expression in Rh4 cells suggesting overlapping functions of PLK1 and PLK4 
(Supplementary Fig. S6). Nevertheless, our findings support the conclusion that PLK1 
regulates PAX3-FOXO1 activity. 
To further sustain this notion, we demonstrated direct protein-protein interaction of the 
endogenous proteins by co-immunoprecipitations in aRMS cells. Also, recombinant 
PLK1 phosphorylated the fusion protein at S503 in in vitro kinase assays. This residue is 
located within a very conserved domain in the FOXO1 part of the fusion protein and the 
corresponding serine in wild type FOXO1 (S322) is a site known to be phosphorylated 
by recombinant CK1 (47). A recent study demonstrated that wild type FOXO1 interacts 
with and is phosphorylated also by PLK1 during G2-M (48). Similarly, we observed 
enhanced interaction in this cell cycle phase. However, phosphorylation of wild type 
FOXO1 triggers nuclear export (47, 48), whereas PAX3-FOXO1 is located exclusively in 
the nucleus (22) (and own observations). Hence, phosphorylation of S503 by PLK1 must 
have different consequences. In fact, we observed faster degradation of PAX3-FOXO1-
S503A compared to wild type after cycloheximide block due to enhanced ubiquitination 
upon PLK1 inhibition. It has previously also been shown that PAX3-FOXO1 has 
increased post-translational stability compared to wild type proteins (21). Our results 
are furthermore in line with studies demonstrating PLK1 to mediate stabilization of 
transcription factors such as the oncogene MYC (49). Interestingly, we found the fusion 
target gene NMYC to be degraded upon PLK1 inhibition, either by a direct or indirect 
mechanism (Supplementary Fig. S7), which might further sensitize aRMS as well as 
other NMYC expressing tumors to PLK1 inhibitors. In accordance with the proposed 
function of PAX3-FOXO1 in checkpoint adaptation (50), PLK1 might prevent premature 
degradation of PAX3-FOXO1 during the transition phase. In summary, this suggests a 
model whereby PLK1 phosphorylation can stabilize PAX3-FOXO1, mainly during G2-M 
 20
transition, whereas at the same time it would inhibit the wild type tumor suppressor 
FOXO1 to ensure cell cycle progression and survival.  
We observed an almost complete tumor regression in vivo upon treatment with BI 2536 
in two different aRMS cell lines. This is in agreement with an objective response 
demonstrated for the Rh30r aRMS xenograft by the Pediatric Preclinical Testing 
Program (51). This particular xenograft was derived from a patient that had failed prior 
therapies suggesting that PLK1 expression might be of prognostic relevance. Indeed, 
expression of PLK1 in 49 aRMS tumor biopsies significantly predicted poor prognosis 
for event free and overall survival. To our knowledge, PLK1 expression is therefore one 
of the first predictive markers next to EPHB4 that is able to stratify patients within the 
group of fusion-positive tumors (52).  
Summarizing, our data suggest that PLK1 is a highly relevant clinical target in aRMS 
with several PLK1 inhibitors already in clinical development. Since it has been shown 
that mice can tolerate higher systemic exposure to PLK1 inhibitors than humans (51), it 
is likely that combination therapies need to be developed to overcome this obstacle. 
Nevertheless, this study reveals an important new role for PLK1 in aRMS biology apart 
from its known function in cell cycle that might explain increased sensitivity. Hence, our 
results should be directly translatable to clinical studies. 
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Figure Legends 
 
Figure 1. siRNA and drug screening identify PLK1 as regulator of PAX3-FOXO1 
(A) Schematic representation of screening strategy. PAX3-FOXO1 is phosphorylated, 
transcriptionally active and induces expression of the luciferase gene, which is under 
the control of the PAX3-FOXO1-responsive AP2β promoter. Kinase silencing and small- 
molecule inhibition reduce PAX3-FOXO1 transcriptional activity and result in a 
decreased expression of the luciferase gene. 
(B) Results of kinome-wide siRNA screen. RNA silencing was carried out for 48h using 
50 nM siRNA. The luciferase readout was normalized to cell viability measured by WST-
1 assay. siRNAs targeting luciferase (pGL4) and PAX3-FOXO1 served as positive controls 
for reduced activity/cell viability ratio (LF/V) and siKIF11 for reduced cell viability. 
Reduced LF/V ratio upon PLK1 silencing is marked in black. Data points, mean of three 
independent experiments performed in triplicates; threshold, 1.5 SDs of mean of 
luciferase knockdown 
(C) Sub-screen of candidate kinases. RNA silencing was carried out in Rh4 and RMS13 
cells for 72h using 50 nM siRNA. Cell viability was measured by WST-1 assay and set 
relative to scrambled knockdown. Data points, mean of three independent experiments 
performed in triplicates; Student’s t-test for PLK1 knockdown *** p < 0.001, ** p < 0.01 
(D) Illustration of the ten most effective drugs. Rh4-AP2β-LF cells were treated with a 
small-molecule compound library at a final concentration of 500 nM for 24h and 
luciferase activity (LF) and cell viability (V) were measured. Relative values compared to 
untreated cells as well as the resulting LF/V ratios are shown. Columns, mean of 
technical triplicates; bars, SD 
(E) Drug response curve of BI 2536 based on LF/V ratio. Rh4-AP2β-LF cells were 
treated with increasing concentrations of BI 2536 for 24h. LF/V values were measured 
relative to untreated cells. Data points, mean of technical triplicates; non-linear 
regression curve fitting using Prism GraphPad 
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(F) PLK1 expression in aRMS cell lines shown by Western blot analysis 
 
Figure 2. PLK1 silencing and inhibition reduce PAX3-FOXO1 activity 
Relative mRNA expression of PAX3-FOXO1 and its target genes upon PLK1 knockdown 
and inhibition. CT values relative to scrambled knockdown or DMSO treatment were 
measured by qRT-PCR and normalized to GAPDH expression.  
(A and B) PLK1 was silenced for 48h using two different sequences (25 nM si1341 and 8 
nM siS449) in RMS13 and Rh4 cells. 
(C and D) RMS13 and Rh4 cells were treated with 15 nM BI 2536 or 20 nM BI 6727 for 
48h. 
Columns, geometric mean of at least 4 independent experiments performed in 
triplicates; bars, 95% confidence interval;  * significant according to 95% CI 
 
Figure 3. PLK1 phosphorylates PAX3-FOXO1 
(A) Western blot analysis showing endogenous Co-IP of PLK1 after PAX3-FOXO1 
immunoprecipitation in Rh4 cells. Beads-only were used as negative control. 
(B) Western blot analysis showing endogenous Co-IP of PAX3-FOXO1 after PLK1 
immunoprecipitation in Rh4 cells. Beads-only were used as negative control. 
(C) Western blot analysis of PLK1 after FLAG immunoprecipitation from Rh4 cells 
expressing FLAG-PAX3-FOXO1. Cells were treated with DMSO or 15 nM BI 2536 for 16h. 
FLAG-GFP was used as negative control. 
(D) In silico analysis using the phospho-site prediction software GPS-Polo 1.0 for 
phosphorylation of PAX3-FOXO1 by PLK   
(E) Western blot analysis of FLAG-PAX3-FOXO1 purified from Rh4 cells using anti 
phospho-S503+S506 antibody 
(F) PLK1 in vitro kinase assay. HEK293T cells were transfected by FLAG-PAX3-FOXO1 
expressing plasmid, purified, dephosphorylated by CIAP and re-phosphorylated by 
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recombinant PLK1. Phospho-peptide identified by mass spectrometric analysis and 
Western blot analysis using anti phospho-S503+S506 antibody are shown. 
 
Figure 4. PLK1 stabilizes PAX3-FOXO1 
(A) Western blot analysis of exogenous, wild type or phospho-mutant PAX3-FOXO1 
degradation. RD cells were transfected with PAX3-FOXO1 wild type or PAX3-FOXO1-
S503A expressing constructs and treated for 6h with DMSO or 35 μM cycloheximide 
(CHX).  
(B) Quantification of exogenous PAX3-FOXO1 degradation by densitometry. Levels were 
normalized to GAPDH. Columns, mean of three independent experiments; bars, SD; 
Student’s t-test ** p= 0.0052 
(C and D) Western blot analysis of endogenous PAX3-FOXO1 degradation upon PLK1 
silencing. RMS13 and Rh4 cells were transfected with 25 nM si1341 or 8 nM siS449 for 
48h.  
(E) Western blot analysis of endogenous PAX3-FOXO1 degradation upon PLK1 
inhibition. RMS13 and Rh4 cells were treated with DMSO, 15 nM BI 2536 or 20 nM BI 
6727 for 48h.  
(F) Ubiquitination studies. Western blot analysis after FLAG immunoprecipitation from 
Rh4 cells expressing FLAG-PAX3-FOXO1 and HA-Ubiquitin. Cells were treated with 
DMSO, 200 nM BI2536 or 200 nM BI6727 for 21h prior to addition of 10 μM MG-132 for 
5h.  
(G) Western blot analysis showing rescue of endogenous PAX3-FOXO1 degradation by 
the proteasomal inhibitor Bortezomib. Rh4 cells were treated with 15 nM BI 2536 for 
20h. Bortezomib was simultaneously titrated to the cells. Densitometric quantification 
normalized to β-Tubulin is indicated.  
 
Figure 5. PLK1 inhibition causes tumor regression in vivo 
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In vivo drug treatment of NOD/Scid il2rg-/- mice engrafted with Rh4 (n=10), Rh4luc 
(n=6) and RMS13luc (n=6) (luc = luciferase expressing). Mice bearing established 
tumors were treated intravenously for three cycles with either vehicle control or BI 
2536 at a dose of 40 mg/kg twice weekly on two consecutive days (indicated by 
triangles).  
(A) Absolute and relative tumor volumes upon treatment. Absolute tumor volume was 
measured by caliper (upper two panels). In vivo imaging was performed for luciferase 
expressing tumors. Relative bioluminescence (photons/second) is depicted (lower four 
panels).  
(B) Illustration of tumor regression by picture series during treatment phase of two 
representative mice  
(C) Immunohistochemistry of a control and a BI 2536 treated tumor. Rh4luc tumors 
were treated for two cycles with either vehicle control or BI 2536 at a dose of 40 mg/kg. 
Tumors were excised two weeks after the end of treatment and immunohistochemically 
stained.  
 
Figure 6. PLK1 is an overexpressed, prognostic marker that correlates with PAX3-
FOXO1 activity in tumor biopsies 
(A) PLK1 gene expression in normal human muscle (n=121) and in PAX3-FOXO1 
positive aRMS patient-derived biopsies (n=46) measured by microarray (Affymetrix HG-
U133A). Box plot, minimum to maximum; Student’s t-test p < 0.0001 
(B) Patient-derived tissue microarray immunohistochemically stained for PLK1 (n=49) 
and AP2β (n=45) expression. Patients were grouped according to high (n=26) and low 
(n=23) PLK1 expression and high (n=28) and low AP2β (n=17) expression. 
Representative tumor of PLK1 high expression cohort and a tumor with very low 
expression are shown next to AP2β staining of the same tumor.  
(C) Pearson correlation of PLK1 and AP2β expression based on tissue microarray 
 29
(n=45); p= 0.0004 
(D) Kaplan-Maier survival curves of PLK1 low and high expression cohorts based on 
tissue microarray.  Log-rank test 
 
0 20 40 60 80 100
BI 2536
Honokiol
NVP-BSK805
PU-H71
AT9283
Danusertib
TG101348
Saracatinib
PKC412
Nilotinib
Rh4-AP2b-LF
LF
V
LF and V relative to control [%]
Figure 1 
siRNA Kinome  
Library 
Small-molecule 
Library 
Kinase Kina 
 Kinase 
Kinase Kina 
  Kinase 
PAX3-FOXO1 
Kinase Kina 
  Kinase 
PAX3-FOXO1 
AP2β promoter Luciferase AP2β promoter 
AP2β promoter Luciferase 
Luciferase 
PAX3-FOXO1 
P 
s
e
q
u
e
n
c
e
 A
s
e
q
u
e
n
c
e
 B
s
e
q
u
e
n
c
e
 C
s
e
q
u
e
n
c
e
 A
s
e
q
u
e
n
c
e
 B
s
e
q
u
e
n
c
e
 C
0.0
0.5
1.0
1.5
2.0
2.5
Rh4 RMS13 kd sample
kd PAX3-
FOXO1 
kd KIF11
kd PLK1
** ** **
*** *** ***re
la
ti
v
e
 c
e
ll
 v
ia
b
il
ity
0 1 2 3
0.0
0.2
0.4
0.6
0.8
1.0
log [BI 2536/nM]
lu
c
if
e
ra
s
e
 a
c
ti
v
it
y
 / 
c
e
ll
 v
ia
b
il
ity
C D 
E F 
0.24 
0.36 
0.38 
0.40 
0.42 
0.49 
0.51 
0.55 
0.55 
0.56 
1.00 
B A 
0 20 40 60 80 100
0.0
0.5
1.0
1.5
2.0
2.5
kd sample
kd scrambled
kd PAX3-FOXO1
kd pGL4
kd KIF11
kd PLK1 
position
lu
c
if
e
ra
s
e
 a
c
ti
v
it
y
 /
 c
e
ll 
v
ia
b
il
ity
relative ratio: 
Figure 2
250
AP2β
FGFR4
CDH3
PLK1
PAX3-FOXO1
MYL1
Rh4 PLK1 knockdown
* *
pr
es
si
on
 [%
]
250
AP2β
FGFR4
CDH3
PLK1
PAX3-FOXO1
MYL1
RMS13 PLK1 knockdown
*
*
pr
es
si
on
 [%
]
A B
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
0
50
100
PIPOX
**
*
*
*
*
*
re
la
tiv
e 
m
R
N
A 
ex
p
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
sc
ra
m
bl
ed
si
13
41
si
S4
49
0
50
100
PIPOX
* *
* *
*
* * * *
*
re
la
tiv
e 
m
R
N
A 
ex
p
C D
50
100
250
AP2β
FGFR4
CDH3
PIPOX
PLK1
PAX3-FOXO1
MYL1
Rh4 drug treatment
*
* *
*
**
* * * *
*
m
R
N
A 
ex
pr
es
si
on
 [%
]
50
100
1000
AP2β
FGFR4
CDH3
PIPOX
PLK1
PAX3-FOXO1
MYL1
RMS13 drug treatment
* *
*
* * *
* * * *
m
R
N
A 
ex
pr
es
si
on
 [%
]
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
0re
la
tiv
e 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
D
M
S
O
BI
 2
53
6 
BI
 6
72
7 
0re
la
tiv
e 
Figure 3 
Input 
Input 
Co-IP 
PAX3-
FOXO1 
PLK1 
IP  
FLAG-
PAX3-
FOXO1 
FLAG-
GFP 
D
M
S
O
 
B
I 
2
5
3
6
 
D
M
S
O
 
B
I 
2
5
3
6
 
130 kDa 
130 kDa 
  70 kDa 
  70 kDa 
C 
Input a
n
ti
 
P
L
K
1
  
PAX3-
FOXO1 
PLK1 
b
e
a
d
s
 
o
n
ly
 
  70 kDa 
130 kDa 
B 
Input a
n
ti
 
F
O
X
O
1
 
PAX3-
FOXO1 
PLK1 
a
n
ti
 
P
A
X
3
 
b
e
a
d
s
 
o
n
ly
 
130 kDa 
  70 kDa 
A 
F 
C
IA
P
 
P
L
K
1
 
PAX3-FOXO1 
PAX3-FOXO1 
phospho S503+S506 
130 kDa 
130 kDa 
Peptide identified by MS: TSSNASTISGR 
Consensus sequence:  NXS 
 
     
5
0
3
  
5
0
4
 
5
0
6
 
IP  
IP  
Input 
PAX3-FOXO1  
phospho S503+S506 
FLAG-
PAX3-
FOXO1 
FLAG-
GFP 
130 kDa 
PAX3-
FOXO1 130 kDa 
130 kDa 
E 
D 
Cut-off:  3.8 
Figure 4
100
150 **
un
t o
f r
es
id
ua
l 
in
 [%
]
BA wt S503A
D
M
S
O
D
M
S
O
C
H
X
C
H
X
130 kDa
wt S503A
0
50
re
la
tiv
e 
am
ou
pr
ot
e
Rh4
bl
ed
9b
le
d
9
RMS13C RMS13
bl
ed
bl
ed
Rh4 D
PAX3-
FOXO1
GAPDH
 
40 kDa
55 kDa
sc
ra
m
b
si
S
44
9
sc
ra
m
b
si
S
44
9
β-Tubulin
PAX3-
FOXO1
PLK1
70 kDa
130 kDaPAX3-
FOXO1
130 kDa
sc
ra
m
b
si
13
41
β Actin
PLK1
sc
ra
m
b
si
13
41
70 kDa
 -
40 kDa
Rh4
E F
D
M
S
O
BI
 2
53
6
BI
 6
72
7
RMS13
PAX3
D
M
S
O
BI
 2
53
6
BI
 6
72
7
130 kDa
FLAG-PAX3-FOXO1  + +         + -
HA-Ubiquitin + +         +         -
BI
 6
72
7
BI
 2
53
6
D
M
S
O
D
M
S
O
IP:
anti FLAG
G
O 36 36
 +
 
zo
m
ib
10
nM
36
 +
zo
m
ib
25
nM
36
 +
 
zo
m
ib
50
nM
zo
m
ib
10
nM
zo
m
ib
25
nM
zo
m
ib
50
nM
β-Actin
-
FOXO1
40 kDa
PAX3-FOXO1-
(ub)n             
IB: anti-HA
FLAG-PAX3-
FOXO1
-
130 kDa
130 kDa
100% 74% 73% 84% 97% 134% 116% 101%
β-Tubulin
PAX3-
FOXO1
D
M
S
O
B
I 2
53
B
I 2
53
B
or
te
z
B
I 2
53
B
or
te
z
B
I 2
53
B
or
te
z
B
or
te
z
B
or
te
z
B
or
te
z
130 kDa
55 kDa
          
IB: anti FLAG
β-Tubulin
FLAG-PAX3-
FOXO1          
IB: anti FLAG
Input
130 kDa
55 kDa
Figure 5 
RMS13luc control
0 5 10 15 20 25
0
250
500
750
days
re
la
ti
v
e
 p
h
o
to
n
s
/s
e
c
 [
%
]
0 5 10 15 20 25
0
250
500
750
1000
Rh4 control
days
tu
m
o
r 
v
o
lu
m
e
 [
m
m
3
]
0 5 10 15 20 25
0
100
200
300
400
Rh4 BI 2536
days
tu
m
o
r 
v
o
lu
m
e
 [
m
m
3
]
A 
Rh4luc control
0 5 10 15 20 25
0
250
500
750
days
re
la
ti
v
e
 p
h
o
to
n
s
/s
e
c
 [
%
]
Rh4luc BI 2536
0 5 10 15 20 25
0
20
40
60
80
100
days
re
la
ti
v
e
 p
h
o
to
n
s
/s
e
c
 [
%
]
RMS13luc BI 2536
0 5 10 15 20 25
0
20
40
60
80
100
days
re
la
ti
v
e
 p
h
o
to
n
s
/s
e
c
 [
%
]
C 
0         4          7       11        14        18 
  days 
299 mm3 4 mm3 158 mm3 4 mm3 
Rh4 RMS13 
B 
0         4         7         11       14       18 
  days 
Luminescence Luminescence 
control BI 2536 
Myogenin 
100 μm 100 μm 
AP2β 
100 μm 100 μm 
P-Cadherin 
100 μm 100 μm 
H&E 
100 μm 100 μm 
D 
Figure 6 
C 
Pearson correlation: p= 0.0004 
PLK1 5yr EFS  95% CI 5yr OS 95% CI 
low 
n=23 
42.4% 26.1-68.8% 59.7% 42.4-84.0% 
high 
n=26 
15.4%  6.2-37.9 % 20.2% 8.6-47.2% 
B 
PLK1 AP2β 
100 μm 10 μm 
A 
normal muscle aRMS (P3F)
0
2
4
6
8
***
P
L
K
1
 g
e
n
e
 e
x
p
re
s
s
io
n
 l
e
v
e
l 
[A
U
]
PLK1 low 
PLK1 high 
Overall Survival 
Log-rank test 
p=0.0023 
PLK1 high 
PLK1 low 
Event Free Survival 
Log-rank test 
p=0.016 
years years 
E
F
S
 p
ro
b
a
b
ili
ty
 
O
S
 p
ro
b
a
b
ili
ty
 
21 
13 
4 
7 PLK1 high / AP2β high 
PLK1 low / AP2β low 
PLK1 high / AP2β low 
PLK1 low / AP2β high 
Table 1. Multivariate Analysis 
 relative risk p-value 
 
Event Free Survival 
Age 0.996 0.892 
Sex (male vs. female) 0.709 0.367 
Localization (unfavorable vs. favorable) 0.704 0.577 
PLK1 (high vs. low) 2.340 0.028 
 
Overall Survival 
Age 1.016 0.571 
Sex (male vs. female) 0.701 0.392 
Localization (unfavorable vs. favorable) 1.230 0.797 
PLK1 (high vs. low) 2.560 0.020 
 
 
